| Zacks Company Profile for Actinium Pharmaceuticals, Inc. (ATNM : AMEX) |
|
|
| |
| • Company Description |
| Actinium Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing ARCs or Antibody Radiation-Conjugates, which combine the targeting ability of antibodies with the cell killing ability of radiation. Actinium's lead application for their ARCs is targeted conditioning, which is intended to selectively deplete a patient's disease or cancer cells and certain immune cells prior to a BMT or Bone Marrow Transplant, Gene Therapy or Adoptive Cell Therapy (ACT) such as CAR-T to enable engraftment of these transplanted cells with minimal toxicities. With their ARC approach, they seek to improve patient outcomes and access to these potentially curative treatments by eliminating or reducing the non-targeted chemotherapy that is used for conditioning in standard practice currently. Their lead product candidate, I-131 apamistamab (Iomab-B) is being studied in the ongoing pivotal Phase 3 Study of Iomab-B in Elderly Relapsed or Refractory Acute Myeloid Leukemia (SIERRA) trial for BMT conditioning. The SI
Number of Employees: 37 |
|
|
| |
| • Price / Volume Information |
| Yesterday's Closing Price: $1.55 |
Daily Weekly Monthly
 |
| 20 Day Moving Average: 469,102 shares |
| Shares Outstanding: 31.20 (millions) |
| Market Capitalization: $48.35 (millions) |
| Beta: -0.32 |
| 52 Week High: $8.64 |
| 52 Week Low: $1.03 |
| Short Interest Ratio: |
| |
% Price Change |
% Price Change Relative to S&P 500 |
| 4 Week |
-2.52% |
-6.17% |
| 12 Week |
28.10% |
7.75% |
| Year To Date |
23.02% |
15.20% |
|
|
|
|
| |
|
|
| |
| • General Corporate Information |
Officers
Sandesh Seth - Chairman and Chief Executive Officer
Steve O'Loughlin - Chief Financial Officer
June Almenoff - Director
Jeffrey Chell - Director
David Nicholson - Director
|
|
Peer Information
Actinium Pharmaceuticals, Inc. (GSAC)
Actinium Pharmaceuticals, Inc. (CASI)
Actinium Pharmaceuticals, Inc. (ALCD.)
Actinium Pharmaceuticals, Inc. (OMNN)
Actinium Pharmaceuticals, Inc. (CGPI.)
Actinium Pharmaceuticals, Inc. (CATX)
|
|
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-DRUGS
Sector: Medical
CUSIP: 00507W206
SIC: 2834
|
|
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/25
Next Expected EPS Date: 08/04/25
|
|
Share - Related Items
Shares Outstanding: 31.20
Most Recent Split Date: 8.00 (0.03:1)
Beta: -0.32
Market Capitalization: $48.35 (millions)
|
|
|
|
|
| |
| • EPS Information |
• Dividend Information |
| Analyst Coverage: No |
Dividend Yield: 0.00% |
| Current Fiscal Quarter EPS Consensus Estimate: $-0.34 |
Indicated Annual Dividend: $0.00 |
| Current Fiscal Year EPS Consensus Estimate: $-1.25 |
Payout Ratio: |
| Number of Estimates in the Fiscal Year Consensus: 3.00 |
Change In Payout Ratio: |
| Estmated Long-Term EPS Growth Rate: % |
Last Dividend Paid: NA - $0.00 |
| Next EPS Report Date: 08/04/25 |
|
|
|
| |
